NZ725567A - R-spondin translocations and methods using the same - Google Patents

R-spondin translocations and methods using the same

Info

Publication number
NZ725567A
NZ725567A NZ72556713A NZ72556713A NZ725567A NZ 725567 A NZ725567 A NZ 725567A NZ 72556713 A NZ72556713 A NZ 72556713A NZ 72556713 A NZ72556713 A NZ 72556713A NZ 725567 A NZ725567 A NZ 725567A
Authority
NZ
New Zealand
Prior art keywords
methods
spondin
same
translocations
spondin translocations
Prior art date
Application number
NZ72556713A
Inventor
Zora Modrusan
SAUVAGE Frederic DE
Steffen Durinck
Somasekar Seshagiri
Eric William Stawiski
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NZ725567A publication Critical patent/NZ725567A/en

Links

Abstract

Disclosed is the use of an antibody that binds R-spondin 2 (RSPO2) and/or R-spondin 3 (RSPO3) for the preparation of a medicament for treatment of colorectal cancer, wherein the cancer or the cancer cell comprises an RSPO2 and/or RSPO3 translocation.
NZ72556713A 2012-02-11 2013-02-11 R-spondin translocations and methods using the same NZ725567A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261597746P 2012-02-11 2012-02-11
US201261674763P 2012-07-23 2012-07-23
NZ62748813 2013-02-11

Publications (1)

Publication Number Publication Date
NZ725567A true NZ725567A (en) 2019-09-27

Family

ID=68318659

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ72556713A NZ725567A (en) 2012-02-11 2013-02-11 R-spondin translocations and methods using the same

Country Status (1)

Country Link
NZ (1) NZ725567A (en)

Similar Documents

Publication Publication Date Title
ZA201907607B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
TN2015000050A1 (en) Methods of treating a tauopathy
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
NZ710929A (en) Antibody drug conjugates
SG10201804338PA (en) Anti-fcrh5 antibodies
MX2015012122A (en) Antibody drug conjugates and corresponding antibodies.
MX2019015604A (en) Methods of treating a tauopathy.
MX340090B (en) Spliceostatin analogs.
PH12014502797A1 (en) Immunoconjugates comprising anti-cd22 antibodies
MX352738B (en) Cytotoxic peptides and antibody drug conjugates thereof.
EP4249065A3 (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
MX2016006726A (en) Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy.
MX2017014338A (en) Targeted selection of patients for treatment with cortistatin derivatives.
PT4095130T (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2014163714A3 (en) Antibody drug conjugates
MX2016004853A (en) ANTI-Ly6E ANTIBODIES AND METHODS OF USE.
EP3006465A4 (en) Anti-vegf antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same
MX2013002718A (en) Anti-vegfr-3 antibody compositions.
MX362497B (en) Methods for treatment of gastric cancer.
NZ725567A (en) R-spondin translocations and methods using the same
NZ626513A (en) Anti-cd98 antibodies and methods of use thereof
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
UA99211C2 (en) Nanocapsules with functions of nanorobot

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed